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According to the recent reports, colorectal cancer is 
the third most frequently diagnosed cancer in the United 
States. In 2005, an estimated 105,950 new cases of 
colon cancer occurred. During the same year, an esti-
mated 55,290 people died from colorectal cancer [1]. 
In China, the incidence of colon cancer has increased 
recently, becoming a major threat to the public health. 
Therefore, improving early detection and treatment, 
especially the efficacy, to reduce mortality and extend 
the patients’ lives are of the greatest concern.
Cyclooxygenase (COX), a rate-limiting enzyme for 
the metabolism of arachidonic acid to prostanoids, 
has two isoforms, constitutive COX-1 and inducible 
COX-2, which were identified in 1991 [2, 3]. COX-1 is 
expressed in quiescent and normal cells, while in normal 
tissue the expression of COX-2 is very low, and, in many 
cases, undetectable. COX-2 expression is induced by 
a variety of factors, including interleukin-1 (IL-1), tis-
sue anoxia, ultraviolet ray exposure, epidermal growth 
factor (EGF), transforming growth factor β (TGF-β), 
tumor necrosis factor-α (TNF-α) and tumor promoters 
[2]. Recent researches have demonstrated that COX-2 
is overexpressed frequently in various gastrointestinal 
tract cancers, such as colorectal cancer, esophageal 
carcinoma, gastric cancer and pancreatic cancer [4].
Epidemiological and clinical observation and labora-
tory research since 1980s have indicated that non-ste-
roidal anti-inflammatory drugs (NSAIDs) played a crucial 
role in tumor inhibition both in vivo and in vitro, particularly 
in gastrointestinal tract cancers [5]. These researches 
indicated that COX-2 is maybe a target of NSAIDs.
Since the development of selective COX-2 inhibi-
tors to treat inflammatory diseases, Steinbach et al. [6] 
first reported in 2000 that in 100 patients with familial 
adenomatous polyposis, six months of twice-daily 
treatment with 400 mg of celecoxib, a COX-2 inhibitor, 
significantly reduced the number of colorectal pol-
yps. More and more studies have demonstrated that 
non-selective NSAIDs, as well as selective COX-2 
inhibitors, can reduce cellular proliferation, induce 
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Aim: To examine the effect of celecoxib on tumor growth and angiogenesis in an orthotopic implantation tumor model of colon cancer. Meth-
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to COX-2 expression (r = 0.8249, P < 0.05). Compared to the control group, the tumor cells from celecoxib-treated mice had a significantly 
higher apoptotic index. Celecoxib also decreased CD34+ expression in tumors from treated mice. There were significant differences in the 
MVD between all groups except between groups H and M. Celecoxib significantly reduced the expression of VEGF and MMP-2 mRNA in 
the group H but not in L and M groups. The MVD in tumor tissue was closely related to the PGE2 levels, as well as the expression of VEGF 
and MMP-2 mRNA (r = 0.9006, r = 0.8573 and r = 0.6427, respectively; P < 0.05). Conclusions: By inhibiting COX-2, PGE2 synthesis, 
and VEGF and MMP-2 mRNA expression in tumor tissue, celecoxib enhances tumor cell apoptosis, thereby inhibiting the growth and 
angiogenesis of orthotopically implanted tumors in a mouse model of human colorectal cancer. 
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apoptosis, promote immunologic surveillance, and/or 
reduce neoangiogenesis. These drugs inhibit tumor 
angiogenesis by both COX-dependent and COX-in-
dependent mechanisms [7–10]. However, the exact 
mechanisms remain poorly understood [11–13].
In this study we established an animal model of or-
thotopic implantation of colon cancer cells to replicate 
the clinical conditions of human colon cancer. We then 
observed the effects of the selective COX-2 inhibitor 
celecoxib on the tumors to investigate its anticancer 
mechanism.
MATERIALS AND METHODS
Cell lines and animal model. The human colorectal 
adenocarcinoma cell line HT-29 was purchased from 
the Institute of Biochemistry and Cell Biology (Shang-
hai Institute for Biological Sciences (SIBS), Chinese 
Acade my of the Sciences (CAS), Shanghai, China) and 
was maintained in McCoy’s 5A medium containing 10% 
fetal bovine serum (GIBCO, USA). Four-week-old female 
BALB/c nu/nu mice (Shanghai Laboratory Animal Center, 
CAS) were maintained under specific pathogen-free 
conditions in a laminar air-flow incubator (25 °C, 40 to 
60% humidity, with a 12 h light-dark cycle). To initiate the 
tumor growth, HT-29 cells in the log phase of growth were 
implanted subcutaneously in nude mice. After 4 weeks, 
small pieces of HT-29 tumor tissue (2 mm x 2 mm in di-
ameter) were resected aseptically during the exponential 
growth phase (4 weeks) and implanted orthotopically on 
the surface of the cecum of 24 nude mice. The cecum 
was carefully exteriorized, and the serosa was injured 
(2 mm x 2 mm in diameter) at the site where the tumor 
was to be implanted. A tumor piece was then fixed on 
each injured site of the serosal surface with an 8-0 Vicryl 
transmural suture. The abdominal wall and skin were 
closed with 8-0 Vicryl sutures [14].
The present study was approved by the ethics com-
mittee of the hospital, and adhered to the tenets of the 
Declaration of Helsinky.
COX-2 inhibitor treatment. The selective COX-2 
inhibitor, celecoxib, was a generous gift of Pharmacia & 
Upjohn Ltd (Suzhou, China). Postoperatively, all animals 
were randomly divided into four groups: control (C), and 
high (H), middle (M), and low (L) doses of celecoxib. Pure 
water or water containing 1.5, 1.0, or 0.5 mg/L celecoxib 
was provided daily for these animals to drink freely [15]. 
The mice were sacrificed at 6 weeks after tumor implanta-
tion. After weighing each animal, the tumors were removed 
and the volume and weight were evaluated. The tumor 
volume was determined using the formula V = L × W2/
2 where L is length and W is width of colon tumor. The rate 
of tumor inhibition (TI) was calculated using the formula 
TI = [(average tumor weight of the control group — ave-
rage tumor weight of the treatment group)/average tumor 
weight of the control group] × 100%.
Histopathology. For histological examination, the 
stomach, intestine, liver and colon of animals were 
excised and fixed in 10% neutral buffered formalin 
after the animals were sacrificed at 6 weeks. Paraffin 
embedded sections (5 μm) were cut and stained with 
hematoxlin and eosin for histological examination by 
a pathologist who was unaware of the treatment as-
signments. If the orthotopically implantated tumors in-
vaded the serosa, muscularis propria, submucosa, or 
mucosa, or there was pathologic damage to either the 
stomach or intestine mucosa, or there were liver me-
tastases, the results were observed and recorded. 
RIA for PGE2. After colon tumor tissue samples 
(50 mg) were washed with 0.9% NS (normal saline), 
these tissues were homogenized in 1 ml of 0.9% NS. 
Then these solutions were centrifuged (7500 rpm, 
10 min). The supernatant (0.1 ml) was collected and 
the content of PGE2 was measured with a PGE2 RIA kit 
(a gift from Jiangsu Institute of Hematology, Suzhou, 
China) according to the manufacturer’s instructions. 
PGE2 values were expressed as picogram per milliliter 
in the tumor tissue homogenate samples.
RT-PCR for VEGF and MMP-2 mRNA. Tumor 
samples were frozen in liquid nitrogen or stored at –80 °C 
for mRNA analysis. Total cellular RNA was extracted from 
the frozen tumor samples using TRIzol Reagent (Sigma, 
MO, USA) according to the manufacturer’s protocol. 
Briefly, 40 mg of tumor tissue was homogenized in 1 ml 
of TRIzol, and then 0.2 ml of chloroform was added, 
and the mixture was centrifuged (12 000 rpm, 15 min, 
4 °C). The aqueous layer, which contained the RNA, 
was carefully aspirated and 0.5 ml of isopropanol was 
added to precipitate the RNA. The resulting solution was 
centrifuged (12 000 rpm, 15 min, 4 °C) and the pellet was 
washed with 0.6 ml of 75% ethanol, then with 0.8 ml of 
100% ethanol and centrifuged again (12 000 rpm, 15 min, 
4 °C). Finally, the pellet containing RNA was dissolved in 
diethyl pyrocarbonate-treated water (DEPC-H2O) and 
was stored frozen at –80 °C until analysis. 
The RNA samples were prepared for RT-PCR 
analysis by first diluting the mixture of total RNA (2 μg) 
and 2 μl random hexamers (0.1 mmol/L) to 15 μl with 
DEPC-H2O and incubated at 70 °C for 5 min. Then, 
after adding 8 μl of 5 × buffer (Promega co. Madison, 
WI,USA), 200 units of Moloneymurine leukemia virus 
reverse transcriptase (Promega), 50 units of RNasin 
(Promega) and 1.25 μl dNTPs (10 mmol/L), the mixture 
was diluted to 25 μl in DEPC-H2O and converted to 
cDNA by incubation at 37 °C for 1 h and 95 °C for 5 min. 
Finally, the cDNA solution was stored at -20 °C. 
PCR was performed using 5 μl of diluted cDNA in a to-
tal volume of 50 μl, including 5 μl 10 × buffer (Promega), 
1 μl dNTPs (10 mmol/L), 4 μl MgC12 (25 mmol/L), 2 μl 
of sense and antisense primers (10 μmol/L) for VEGF or 
MMP-2, 2 μl of sense and antisense primers (10 μmol/L) 
for β-actin, and 2.5 units of Taq Polymerase (Promega). 
Sequences of the primers for the human VEGF, MMP-
2 and β-actin are shown in Table 1. The samples were 
amplified for 30 cycles of PCR reaction in which pre-
denaturation was done for 5 min at 94 °C, denaturation 
for 30 s, and extension for 3 min at 72 °C. Annealing time 
was 30 s; however, the annealing temperature was 60 °C 
for VEGF transcript and 62 °C for MMP-2. After 30 cycles, 
the product of the PCR reaction was stored for 7 min at 
72 °C and then analyzed. 
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Amplified cDNAs were separated by electropho-
resis on a 1.5% agarose gel containing ethidium 
bromide. The density of the electrophoretic band for 
each amplification product was evaluated using the 
BioCaptMW software. The mRNA values are expressed 
as relative units calculated according to the following 
formula: density of the VEGF or MMP-2 amplification 
product/density of the β-actin amplification product.
Immunohistochemistry for COX-2 protein. Tis-
sue samples were embedded in paraffin, cut into 5 μm 
sections, deparaffinized, and subjected to microwave 
irradiation for 15 min at 92 to 98 °C in 0.01 M Citric acid 
buffer (pH 6.0). Then the slides were immersed in 1% 
H2O2 for 30 min to neutralize endogenous peroxidases. 
The primary antibody against COX-2 (anti-human COX-
2 mouse IgG, Cayman Chemical, USA) was applied to 
tissue sections at a dilution of 1 : 100 and incubated 
overnight at 4 °C. The secondary antibody and en-
zymes were obtained in an Ultravision Detection Sys-
tem kit (Lab Vision, USA). The reaction products were 
visualized using streptavidin-biotin-peroxidase and 3, 
3`-diaminobenzidene chromogen. Finally, the sections 
were counterstained with hematoxylin, dehydrated, 
and mounted in diphenylxylene. The expression level 
of COX-2 was calculated by multiplying a quantitative 
measure of the extent of COX-2 staining extent by 
the quantitative measure of the staining intensity. The 
COX-2 positive staining extent was recorded using 
a 5-grade system, based on the percentage of tumor 
cells stained: grade 0 = 0% to 4%; grade 1 = 5% to 
24%; grade 2 = 25% to 49%; grade 3 = 50% to 74%; 
and grade 4 = 75% to 100%. Staining intensity was 
recorded using 3-grade system: grade 0 = negative; 
1 = weakly positive; 2 = positive. All slides were inde-
pendently evaluated by two blinded observers, both 
of whom were experienced pathologists. 
Assay for microvessel density (MVD). Microves-
sels in the tumor tissue were immunostained using 
anti-human CD34 mouse monoclonal antibody and 
the streptavidin-biotin-peroxidase complex technique 
(Lab Vision, USA). MVD was evaluated according to the 
method first described by Weidner et al. [20]. The entire 
tumor sections was observed under a light microscope 
(Magnification: 40 x) to find the area that showed the 
most intense microvessel density, i.e. the highest density 
of brown stained CD34-positive cells (also referred to 
as the hot spot). Three different areas within a section 
were chosen and the stained microvessels were counted 
under a light microscope at 200x magnification. The aver-
age count was considered the MVD for each slide. 
Assessing the apoptotic index (AI). Terminal 
deoxynucleotidyl transferase-mediated dUTP nick-end 
labeling (TUNEL) was performed using a commercial 
kit (In Situ Cell Detection kit, POD, Roche Diagnostics, 
Germany) according to the manufacturer’s instruc-
tions. By this method, the nuclei of apoptotic tumor 
cells were stained brown. One thousand tumor cells, 
including the apoptotic tumor cells, were counted 
for each sample. The apoptotic index (AI) was calcu-
lated as follows: AI (%) = (number of apoptotic tumor 
cells/1000) × 100. 
Statistical analysis. The data are expressed as the 
mean plus or minus the standard deviation (SD). Analyses 
between multiple groups were determined by ANOVA. 
Analyses between two groups were determined using the 
SNK test. The relationships between PGE2 and the weight 
of tumor, between MVD and the PGE2, between COX-
2 expression and the PGE2, between MVD and VEGF 
mRNA expression and between MVD and MMP-2 mRNA 
expression were examined by simple linear regression 
analysis. All statistical analyses were performed using a 
statistical software package (SPSS, Version 10.0, USA). 
Statistical significance was defined as P-values less than 
0.05. All P-values were two-sided.
RESULTS
General Observations. None of the nude mice 
died after implantation and all animals formed colorec-
tal tumor masses before sacrifice. Three animals in 
group C could touch the mass (about 4 mm in diam-
eter) on the inferior belly in the third week. After all ani-
mals were sacrificed, opening the abdominal cavity of 
each animal revealed masses whose size ranged from 
0.50 cm × 0.45 cm to 1.35 cm × 0.95 cm (Fig. 1, a). 
In addition, staining with haematoxlin and eosin con-
firmed that, in some animals, the tumor cells both the 
muscularis propria and submucosa (Fig. 1, b).
The mean body weight of the control animals was 
lower than in the treatment groups, but the difference was 
not statistically significant (P > 0.05; Fig. 2). However, the 
volume and weight of the tumor in group C were signifi-
cantly higher than in the treatment groups, and were sig-
nificantly different among all groups (P < 0.05; Table 2). 
Tumor growth was inhibited by 25.30% in the L group, 
38.80% in the M group, and 76.92% in the H group, as 
compared to the control group. No obvious ascites was 
found in the abdominal cavity of any animal. 
Also, no animal showed signs of liver metastasis, 
hyperemia, edema, erosion, bleeding or ulceration 
of the stomach and intestine mucosa, confirmed by 
histopathology.
PGE2 levels and COX-2 immunohistochemistry. 
The PGE2 is one important product of metabolism of 
arachidonic acid to prostanoids. The COX-2 plays a 
role in this process. By measuring the PGE2 levels, we 
can analyze the activity of COX-2. In our research, the 
PGE2 levels in the tumor tissue were higher in group 
C than that in the treatment groups (P < 0.05). With 
increasing doses of celecoxib, the PGE2 levels in the 
treatment groups were reduced (P < 0.05; Table 3).
Table 1. RT-PCR primers
Sense Antisense Product size (bp) Refe rence
β-actin ATCTGGCACCACACCTTCTACAATGAGCTGCG CGTCATACTCCTGTGATCCACATCTGC 838 16
VEGF GGGCCTCCGAAACCATGAACTT CGCATCAGGGGCACACAG 259 17
β-actin GAAACTACCTTCAACTCCATC CGAGGCCAGGATGGAGCCGCC 219 18
MMP-2 ACCTGGATGCCGTCGTGGAC TGTGGCAGCACCAGGGCAGC 447 19
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a
b
Fig. 1. Macroscopic and microscopic appearance of ortho-
topically implanted tumors in a mouse model of colon cancer. 
a: Different tumor masses were found in the colon of each animal, 
and celecoxib obviously inhibited the growth of tumor. b: Staining 
with haematoxlin and eosin showed that the tumor cells invaded 
muscularis propria and submucosa (Magnification: × 400)
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Fig. 2. Celecoxib did not alter the mean body weight of animals 
in this study. While the mean body weight of group C animals 
was lower than in the treatment groups, there was no statistically 
significant difference among all groups (P > 0.05)
Table 2. The volume and weight of colon tumor in situa
Group volume of tumor, cm3 weight of tumor, g
C 0.53 ± 0.07* 0.59 ± 0.06*
L 0.34 ± 0.10* 0.44 ± 0.08*
M 0.25 ± 0.05* 0.36 ± 0.05*
H 0.06 ± 0.03* 0.14 ± 0.03*
Note: aValues represent the mean ± SD; *P < 0.05 between all groups.
Table 3. The level of PGE2 and COX-2 expression in tumor tissuea
Group PGE2 pg/mL COX-2
C 608.88 ± 76.71* 8.67 ± 1.03**
L 425.27 ± 71.70* 6.83 ± 1.17** b
M 244.77 ± 29.04* 5.50 ± 1.05**b
H 97.92 ± 15.57* 3.83 ± 1.17**
Notes: aValues represent the mean ± SD; *P < 0.05; bThere were significant 
differences in the COX-2 expression of tumor tissue between all groups 
except between L and M groups; **P < 0.05.
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Fig. 3. Expression of COX-2 in tumor tissue as determined by 
immunostaining. COX-2 expression was detected using the 
streptavidin-biotin-peroxidase method as described in the Mate-
rials and Methods section The extent of COX-2 expression in the 
treatment groups (group L, M and H) decreased gradually with 
the increasing dose of celecoxib. (Magnification: X 400)
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The expression of COX-2 in the tumor tissue was 
higher in group C than in the treatment groups (P < 0.05). 
There were significant differences between all groups 
except the L and M groups in COX-2 expression in tu-
mor tissue (P < 0.05), and the expression decreased 
correspondingly with the increasing dose of celecoxib 
(Table 3, Fig. 3). In addition, the PGE2 levels corre-
lated positively with the weight of the tumor (r = 0.8814, 
P < 0.05; Fig. 4, a). Between the PGE2 level and the 
extent of COX-2 expression significant association was 
also seen (r = 0.8249, P < 0.05; Fig. 4, b). By inhibiting 
COX-2, celecoxib could reduce synthesis of PGE2 in the 
tumor tissue with the increasing dose of celecoxib.
Fig. 4. Correlation between PGE2 and either the weight of 
the tumor (a) or the expression of COX-2 (b). The correlation 
coefficient between PGE2 and the weight of tumor was 0.8814 
(P < 0.05), whereas the correlation coefficient between PGE2 
and expression of COX-2 was 0.8249 (P < 0.05)
Apoptosis in the tumor cells. Apoptosis of the 
tumor cells was detected by TUNEL assay to determine 
the apoptotic index (AI) in the different groups. Our 
experiment showed that the AI was significantly lower 
in group C (2.77 ± 0.70) than in the treatment groups 
(P < 0.05) (Fig. 5). As the dose of celecoxib increased, 
so did the AI, from 5.90 (± 0.65) in the L group, to 
7.47 (± 0.96) in the M group and 9.27 (± 0.97) in the 
H group. These differences were statistically significant 
(P < 0.05). The results revealed that celecoxib could 
dose-dependently enhance tumor cell apoptosis.
Microvessel density (MVD). The MVD is the impor-
tant biomarker for angiogenesis of tumor. Our experiment 
investigated the anti- angiogenesis of celecoxib by mea-
suring the MVD in the tumor tissue. The MVD in group C 
(30.50 ± 4.60) was significantly higher than in the treat-
ment groups (P < 0.05). Celecoxib obviously decreased 
the MVD of groups L (24.33 ± 3.78), M (13.17 ± 3.19), 
and H (9.00 ± 3.58). There were significant differences in 
c
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Fig. 5. Detection of apoptotic HT-29 cells by the TUNEL assay. The 
apoptosis of the tumor cells was detected using the TUNEL method 
as described in the Materials and Methods section. TUNEL-positive 
cells (apoptotic cells) are stained brown (Magnification: × 400). 
There were more apoptotic cells in the samples from celecoxib-
treated mice than in the samples from the control group
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the MVD (P < 0.05) between all groups except between 
groups H and M (Fig. 6). A  significant correlation was 
found between MVD and PGE2 levels in the tumor (r = 
0.9006, P < 0.05; Fig. 7). The results showed that cele-
coxib could inhibit the angiogenesis of tumor and PGE2 
could have a significant correlation with angiogenesis.
Fig. 7. Correlation between PGE2 and MVD in tumors from ce-
lecoxib-treated mice. The correlation coefficient between PGE2 
and MVD was 0.9006 (P < 0.05)
VEGF and MMP-2 mRNA expression. VEGF and 
MMP-2 play an important role in the angiogenesis of 
tumor. Additionally MMP-2 might correlate to invasion 
and metastasis of tumor. Our experiment showed that 
celecoxib significantly reduced the expression of VEGF 
and MMP-2 mRNA in the treatment groups compared 
with to the control group (P < 0.05). There were signifi-
cant differences in the expression of VEGF and MMP-2 
mRNA (P < 0.05) between all groups except groups L 
and M (Table 4, Fig. 8 and 9). 
Table 4. Expression levels of VEGF mRNA and MMP-2 mRNA in tumor tissuea
Group VEGF/β-actin MMP-2/β-actin
C 0.66 ± 0.10* 0.59 ± 0.14**
L 0.49 ± 0.06*b 0.42 ± 0.04**c
M 0.43 ± 0.08*b 0.34 ± 0.06**c
H 0.23 ± 0.06* 0.22 ± 0.08**
Notes: aValues represent the mean ± SD; bThere were significant diffe-
rences in the expression levels of VEGF mRNA between all groups except 
between group L and M; *P <0.05; cThere were significant differences in 
the expression levels of MMP-2 mRNA between all groups except between 
groups L and M; **P < 0.05.
Fig. 8. Expression of VEGF mRNA in tumor tissue as determined 
by RT-PCR. 
Fig. 9. Expression of MMP-2 mRNA in tumor tissue as deter-
mined by RT-PCR
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Fig. 6. Detection of microvessels in tumor tissue by immu-
nostaining for CD34. CD34 expression was detected using 
the streptavidin-biotin-peroxidase method as described in the 
Materials and Methods section. The microvessels were more 
numerous in the control group than in the treatment groups 
(Magnification: × 200)
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In addition, the MVD of tumor tissue significantly 
correlated to the expression of VEGF and MMP-2 mRNA 
in the tumor tissue (r = 0.8573, r = 0.6427, respectively; 
P < 0.05; Fig. 10, A and B). By inhibiting VEGF and 
MMP-2 mRNA expression in tumor tissue, celecoxib 
inhibited the angiogenesis of colorectal cancer
Fig. 10. Correlation between MVD and the expression of VEGF 
(a) and MMP-2 mRNA (b) in tumor tissue. The correlation coef-
ficient between MVD and the expression of VEGF mRNA was 
0.8573 (P <0.05), whereas the coefficient between MVD and 
expression of MMP-2 mRNA was 0.6427 (P < 0.05)
DISCUSSION
In the past 20 years, epidemiological, molecular 
and clinical studies have proved that COX-2 plays an in-
creasingly important role in the occurrence and devel-
opment of colon cancer by various mechanisms [5, 12, 
13]. Since selective COX-2 inhibitors (e.g. celecoxib) 
have lower toxicity and side effects compared to the 
traditional NSAIDs (e.g. aspirin, sulindac, piroxicam, 
ibuprofen, ibuprofen, and indomethacin), we have 
investigated the effect of celecoxib on the growth and 
angiogenesis of orthotopically implanted tumors in 
a mouse model of human colon cancer [21–24].
Our first priority was to establish a suitable pre-
clinical animal model. According to the ‘seed and soil’ 
theory of S. Paget, the animal model of orthotopic 
implantation of colon cancer is the most suitable to 
study the anti-cancer mechanism of celecoxib, 
because this model more accurately replicates the 
clinical condition of human colon cancer, thereby more 
accurately reflecting the efficacy of celecoxib against 
colon carcinoma. In this study, none of the nude mice 
died and all animals formed an in situ mass consistent 
with colorectal tumor. Though liver or lymphoid node 
metastasis and ascites were not found because of the 
relatively short observation time and the biological 
character of HT-29 cells, this model still contributes to 
the study of the local biology behavior and pathophysi-
ological changes of colon cancer. 
This study showed that both the volume and weight 
of the tumor can be reduced significantly by cele-
coxib treatment. This effect was dose-dependent, as 
demonstrated by the rate of tumor growth inhibition. 
Moreover, this effect can be seen even at the lowest 
dose of celecoxib (0.5 mg/L). 
There are many possible anticancer mechanisms 
of celecoxib. The most obvious is the inhibition of 
COX-2 activity [2]. By inhibiting the enzyme activity 
of COX-2, celecoxib reduces the synthesis of PGE2. 
PGE2 might enhance the proliferation and invasive 
potential of colon carcinoma cells by activating major 
intracellular signal transduction pathways [25], such 
as cAMP/PAK/EP [26], c-Met-R/β-catenin [27], 
Raf/MEK/ERK [28], among others. In addition, recent 
reports show that PGE2 stimulates angiogenesis, which 
provides oxygen and nutrients essential for tumor 
growing [29]. The positive correlation in this study be-
tween PGE2 levels and the weight of the tumor shows 
that, by inhibiting the activity of COX-2, celecoxib re-
duced the synthesis of PGE2 and the growth of tumor 
is suppressed. 
Celecoxib might exert its effect by reducing the 
expression of COX-2. In this study, the expression of 
COX-2 is lower in the treatment groups than in the 
control group, resulting in the inhibition of the synthesis 
of PGE2. COX-2 expression could be suppressed by 
a few possible mechanisms. Tjandrawnata et al. [30] 
found that PGE2 can up-regulate the expression of 
COX-2mRNA. When PGE2 levels are reduced, COX-2 ex-
pression decreases, which further suppresses the syn-
thesis of PGE2. Alternatively, the findings of Chun et al. 
[31] suggest that celecoxib can down-regulate COX-2 
expression by blocking activation of p38 mitogen-acti-
vated protein (MAP) kinase and the transcription factor 
AP-1. Finally, Shishodia et al. [32] have reported that 
celecoxib inhibits NF-κB activation through inhibition 
of IKK and Akt activation, leading to down-regulation 
of synthesis of COX-2. Thereby, not only by directly 
inhibiting the activity of COX-2, but by down-regulating 
the synthesis of COX-2, celecoxib takes effect.
In this study, the TUNEL assay was used to detect 
apoptosis, demonstrating that more HT-29 cells under-
went apoptosis in the treatment groups than in the control 
group. These data also show that celecoxib enhanced 
apoptosis of colon cancer cells in a dose-dependent 
manner. Recent reports have implicated many different 
mechanisms in the induction of apoptosis in tumor cells 
by celecoxib. First, PGE2 can inhibit apoptosis by induc-
ing expression of the Bcl-2 proto-oncogene. Also, PGE2 
and other prostaglandins often elevate intracellular cAMP 
concentrations, which can suppress apoptosis. COX-2 
inhibitors may prevent colon cancer by interfering with 
both or either of the above processes [25]. 
Alternatively, Arico et al. [33] have reported that 
celecoxib induces apoptosis through the major anti-
apoptotic PDK1/Akt/PKB signal transduction pathway. 
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Another possible mechanism, reported by Wu et al. 
[34], is activation of caspase-9 and caspase-3, and 
release of cytochrome C in a Bcl-2-independent man-
ner. Grosch et al. [35] indicated that celecoxib can 
inhibit the transition from the G0/G1 to the S phase of 
the cell cycle in colon cancer cells in a concentration-
dependent manner, and induce apoptosis in HT-29 
cells. Moreover, this study showed that the effects of 
celecoxib were independent of the COX-2 status of the 
cells, strongly suggesting that the anticancer activity of 
celecoxib is independent of its ability to inhibit COX-2. 
In other studies, the mechanisms by which selective 
COX-2 inhibitors induce apoptosis in cancer cells also 
was found to be COX-2 independent, by affecting 
such pathways as the 15-lipoxygenase-1 [36], PPAR-δ 
[2, 37] and NF-κB [38] pathways, for example. So, 
celecoxib might induce the apoptosis of colon cancer 
cells by dependent and independent pathways.
Angiogenesis plays a critical role in providing oxygen 
and nutrients essential for tumor growth. Antiangiogenic 
therapy has great potential to become the new method 
for conquering cancer in the future [39]. In recent studies, 
there is evidence that COX-2 may indirectly induce angio-
genesis in vitro by increasing the production of angiogenic 
factors, such as VEGF. In these studies, selective COX-2 
inhibitors were shown to be antiangiogenic [7]. 
Our study also showed that celecoxib suppressed 
angiogenesis in the treatment groups. The MVD of tu-
mors from mice treated with celecoxib was lower than 
in the control group. Additionally, celecoxib significantly 
decreased the expression of VEGF and MMP-2 mRNA in 
the treatment groups compared with the control group. 
Both VEGF and MMP-2 expression are closely related 
to angiogenesis. VEGF has been described as the fun-
damental and strongest regulator of angiogenesis and 
vascular permeability [7]. Celecoxib suppresses the ex-
pression of VEGF by inhibiting the synthesis of PGE2 and 
the activation of the EPR/cAMP/PKA signal transduction 
pathway by which the expression of VEGF was upregu-
lated [7, 40]. This pathway is the primary mechanism by 
which selective COX-2 inhibitors prevent angiogenesis. 
In our study positive correlations between MVD and 
PGE2 levels and VEGF mRNA were the best evidence 
of celecoxib inhibiting this signal pathway.
MMP-2 plays an important role in matrix degrada-
tion, an important process in tumor angiogenesis. 
Moreover, the digestion of vascular basement mem-
branes and an invasive/angiogenic phenotype has been 
closely associated with the overexpression of MMP-2. 
When the basement membranes are deg raded, growth 
factors are released which can promote tumor angio-
genesis [41]. Recently Takahashi et al. [42] reported that 
overexpression of COX-2 in tumor cells up-regulated 
the expression of MMP-2, an effect which is blocked 
by selective COX-2 inhibitors. The results of our study 
also showed that celecoxib suppressed the expression 
of MMP-2. Moreover, the expression of MMP-2 was 
positively related to the MVD. This is another prob-
able mechanism of antiangiogenesis by a selective 
COX-2 inhibitor. There are two potential mechanisms 
by selective COX-2 inhibitors suppress the expression 
of MMP-2. The first is by suppressing transcription of 
MMP-2 [43], which is probably a COX-2-independent 
effect. The second was described by Attiga et al. [44], 
that selective COX-2 inhibitors suppress the synthesis 
of MMP-2 by decreasing the COX-2 metabolites which 
stimulate the synthesis of MMP-2. There are other po-
tential mechanisms by which selective COX-2 inhibitors 
inhibit angiogensis, such as inhibiting TXA2, alpha V beta 
3 integrin, MARK/ERK2 and Akt/GSK signal pathway.
In summary, this study tested the hypothesis that the 
selective COX-2 inhibitor celecoxib can inhibit the growth 
and angiogenesis of orthotopically implanted tumors in 
a mouse model of human colon cancer by suppressing 
COX-2, the synthesis of PGE2 and the expression of VEGF 
mRNA and MMP-2 mRNA. We did not find any pathologic 
damage of gastrointestinal tract in any animals, sug-
gesting that celecoxib may have minimal side effects, as 
least in the gastrointestinal tract, in a clinical setting. The 
further development of safer selective COX-2 inhibitors 
could be a promising approach for the treatment of colon 
cancer. However, celecoxib alone did not induce com-
plete tumor regression in our study. Accordingly, a careful 
study of combination therapy with chemotherapeutic 
agents, or radiotherapy, could lead to more successful 
and promising treatment for colon cancer [45].
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ЦЕЛЕКОКСИБ ИНГИБИРУЕТ РОСТ ОПУХОЛИ И АНГИОГЕНЕЗ 
ПРИ ОРТОТОПИЧЕСКОЙ ИМПЛАНТАЦИИ РАКА ТОЛСТОЙ 
КИШКИ ЧЕЛОВЕКА 
Цель: изучить влияние целекоксиба на рост опухоли и ангиогенез в модели ортопической имплантации опухоли толстой кишки 
человека. Методы: клетки колоректальной аденокарциномы человека НT-29 подкожно имплантировали бестимусным мышам. 
После имплантации опухоли четыре группы животных получали разные дозы целекоксиба. Через 42 дня изучали изменения 
веса животных, объем опухолей, эффект ингибирования роста опухоли. С помощью радиоиммунного анализа (RIA) в гомо-
генате опухолей определяли содержание простогландина E2 (PGE2). В опухолевой ткани иммуногистохимическим методом 
выявляли экспрессию циклооксигеназы-2 (COX-2) и CD34 и оценивали плотность микрососудов (MVD). Апоптотические 
клетки выявляли методом TUNEL. Экспрессия мРНК фактора роста эндотелия сосудов (VEGF) и металлопротеиназы-2 
(MMP-2) в опухолях проанализирована методом обратной транскриптазной реакции (RT-PCR). Результаты: статисти-
чески достоверных различий в весе животных между разными группами обнаружено не было. Вто же время, с увеличением 
дозы целекоксиба объем и вес опухоли уменьшался. По сравнению с контрольной группой (C), рост опухоли статистически 
достоверно ингибировался в L (низкая доза), M (средняя доза) и H (высокая доза) группах животных на 25,30%, 38,80% и 
76,92% соответственно. Были обнаружены значительные отличия в экспрессии COX-2 в опухолевых тканях между всеми 
группами животных, кроме групп L и M. Было показано целекоксиб-зависимое уменьшение уровня PGE2 в гомогенатах 
опухолей. Уровень PGE2 коррелировал с весом опухоли (r = 0,8814, P < 0,05) и экспрессией COX-2 (r = 0,8249, P < 0,05). 
По сравнению с контрольной группой опухолевые клетки мышей, получавших целекоксиб, имели значительно более высокий 
апоптотический индекс. Целекоксиб также снижал экспрессию CD34+ на поверхности опухолевых клеток. Были обнаружены 
статистически достоверные различия в MVD между всеми исследованными группами, кроме H и M. Целекоксиб способствовал 
уменьшению экспрессии мРНК VEGF и MMP-2 в группе Н, но не в группах L и M. MVD в опухолевой ткани кореллировал с 
уровнем PGE2, а также с экспрессией мРНК VEGF и MMP-2 (r = 0,9006, r = 0,8573 и r = 0,6427 соответственно; P < 0,05). 
Выводы: целекоксиб способствует апоптозу опухолевых клеток, ингибирует рост опухоли и ангиогенез при ортотопической 
имплантации мышам колоректальной аденокарциномы человека. Такой эффект целекоксиба связан с угнетением синтеза 
COX-2, PGE2 и экспрессии мРНК VEGF и MMP-2 в опухолевой ткани. 
Ключевые слова: рак толстой кишки, ортотопическая имплантация, циклооксигеназа-2, ангиогенез, простогландин E2.
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